Gilead Sciences (GILD) ROE - Return on Equity
Current and historical Return on Equity (ROE) values for Gilead Sciences (GILD) over the last 10 years.
|Medical||Medical - Biomedical and Genetics||$96.951B||$30.390B|
|Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. They strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Gilead Sciences portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.|